Day One Biopharmaceuticals IncQ) expected to post a loss of 36 cents a share - Earnings Preview
Day One Biopharmaceuticals IncQ) is expected to report a loss of 36 cents per share and a 330.9% increase in quarterly revenue to $35.301 million for the period ending June 30, 2025. The average analyst rating is "buy," with a median 12-month price target of $25.00, reflecting a potential upside of 73.2% from the last closing price of $6.71. The earnings estimates have remained unchanged over the last three months, with previous quarterly performances showing mixed results against estimates.
- Day One Biopharmaceuticals Inc (DAWN.OQ) (DAWN.O) is expected to
show a rise in quarterly revenue when it reports results on August 5 for the period ending June 30 2025
- The Brisbane California California-based company is expected to report a 330.9% increase in revenue to $35.301 million from $8.19 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
- LSEG’s mean analyst estimate for Day One Biopharmaceuticals Inc is for a loss of 36 cents per share.
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 8 “strong buy” or “buy,” 1 “hold” and no “sell” or “strong sell.”
- The mean earnings estimate of analysts was unchanged in the last three months.
- Wall Street’s median 12-month price target for Day One Biopharmaceuticals Inc is $25.00, about 73.2% above its last closing price of $6.71 Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2025 -0.44 -0.44 -0.35 Beat 20.9
Dec. 31 2025 -0.36 -0.36 -0.64 Missed -76.8
Sep. 30 2024 -0.42 -0.41 -0.37 Beat 9.8
Jun. 30 2024 -0.77 -0.75 -0.05 Beat 93.3
Mar. -0.66 -0.66 -0.72 Missed -8.5
31 2024
Dec. 31 2023 -0.59 -0.58 -0.64 Missed -9.7
Sep. 30 2023 -0.59 -0.60 -0.54 Beat 10.3
Jun. 30 2023 -0.61 -0.61 -0.61 Met 0
This summary was machine generated August 1 at 21:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
